Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Henrich JA"'
Autor:
Henrich Janus
Publikováno v:
Pedagogická Orientace, Vol 1, Iss 2 (2018)
N/A
Externí odkaz:
https://doaj.org/article/d590c754030241a7ac0638006b22c5db
Autor:
Heikamp, EB, Henrich, JA, Perner, F, Wong, EM, Hatton, C, Wen, Y, Barwe, S, Gopalakrishnapillai, A, Xu, H, Uckelmann, HJ, Takao, S, Kazansky, Y, Pikman, Y, McGeehan, GM, Kolb, EA, Kentsis, A, Armstrong, SA
Publikováno v:
Blood; 20210101, Issue: Preprints
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Heikamp EB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA., Martucci C; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA., Henrich JA; Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA., Neel DS; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA., Mahendra-Rajah S; Vanderbilt University, College of Arts and Sciences, Nashville, TN 37235, USA., Rice H; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA., Wenge DV; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA., Perner F; Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), 30625 Hannover, Germany., Wen Y; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA., Hatton C; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA., Armstrong SA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA. Electronic address: scott_armstrong@dfci.harvard.edu.
Publikováno v:
Cell reports [Cell Rep] 2024 Oct 29; Vol. 43 (11), pp. 114901. Date of Electronic Publication: 2024 Oct 29.
Autor:
Bourgeois W; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Cutler JA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Aubrey BJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Wenge DV; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Perner F; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.; Internal Medicine C, University Medicine Greifswald, Greifswald, Germany., Martucci C; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Henrich JA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Klega K; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Boileau M; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Wen Y; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Hatton C; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Apazidis AA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Olsen SN; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Kirmani N; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA., Pikman Y; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Pollard JA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Perry JA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Howard Hughes Medical Institute, Boston, MA., McGeehan GM; Syndax Pharmaceuticals, Waltham, MA., Crompton BD; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Armstrong SA; Division of Hematology/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Publikováno v:
Blood [Blood] 2024 Apr 11; Vol. 143 (15), pp. 1513-1527.
Autor:
Aubrey BJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Cutler JA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bourgeois W; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Gu S; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Hatton C; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Perlee S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Perner F; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Internal Medicine C, Universitaetsmedizin Greifswald, Greifswald, Germany., Rahnamoun H; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Theall ACP; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Henrich JA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Zhu Q; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Kim YJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Parvin S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cremer A; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Hematology-Oncology, University Hospital Frankfurt, Frankfurt/Main, Germany.; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany., Olsen SN; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Eleuteri NA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Pikman Y; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA., McGeehan GM; Syndax Pharmaceuticals, Waltham, MA, USA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA., Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Liu XS; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Armstrong SA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. scott_armstrong@dfci.harvard.edu.; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, USA. scott_armstrong@dfci.harvard.edu.
Publikováno v:
Nature cancer [Nat Cancer] 2022 May; Vol. 3 (5), pp. 595-613. Date of Electronic Publication: 2022 May 09.
Autor:
Heikamp EB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Henrich JA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Perner F; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.; Internal Medicine C, Greifswald University Medical Center, Greifswald, Germany., Wong EM; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Hatton C; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Wen Y; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Barwe SP; Nemours Center for Cancer and Blood Disorders/Alfred I. DuPont Hospital for Children, Wilmington, DE., Gopalakrishnapillai A; Nemours Center for Cancer and Blood Disorders/Alfred I. DuPont Hospital for Children, Wilmington, DE., Xu H; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Uckelmann HJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., Takao S; Tow Center for Developmental Oncology, Sloan Kettering Institute, and Department of Pediatrics, Weill Medical College of Cornell University, and Memorial Sloan-Kettering Cancer Center, New York, NY; and., Kazansky Y; Tow Center for Developmental Oncology, Sloan Kettering Institute, and Department of Pediatrics, Weill Medical College of Cornell University, and Memorial Sloan-Kettering Cancer Center, New York, NY; and., Pikman Y; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA., McGeehan GM; Syndax Pharmaceuticals, Inc., Waltham, MA., Kolb EA; Nemours Center for Cancer and Blood Disorders/Alfred I. DuPont Hospital for Children, Wilmington, DE., Kentsis A; Tow Center for Developmental Oncology, Sloan Kettering Institute, and Department of Pediatrics, Weill Medical College of Cornell University, and Memorial Sloan-Kettering Cancer Center, New York, NY; and., Armstrong SA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
Publikováno v:
Blood [Blood] 2022 Feb 10; Vol. 139 (6), pp. 894-906.